Literature DB >> 8531088

Vasorelaxing effect of S-nitrosocaptopril on dog coronary arteries: no cross-tolerance with nitroglycerin.

T Matsumoto1, M Takahashi, I Nakae, M Kinoshita.   

Abstract

S-Nitrosocaptopril (S-NO-Cap) produced dose-dependent relaxation in isolated dog coronary arteries. This relaxation consisted of two parts: an initial phasic relaxation and a subsequent sustained relaxation. Relaxation was potentiated by superoxide dismutase but was suppressed by pyrogallol, methylene blue or oxyhemoglobin. The relaxant responses of coronary artery to vasoactive agents were reexamined after the development of nitrate tolerance induced by a 1-hr treatment with 4.4 x 10(-4) M nitroglycerin (NTG). NTG tolerance was verified by a 40-fold increase in the EC50 values. The relaxant response to nitroprusside was only marginally suppressed in NTG-tolerant arteries. NTG-tolerant arteries were not tolerant to nitric oxide (NO) or 8-bromo-cyclic guanosine monophosphate (cGMP) and did not show a significant change in the concentration-response curves. Similarly, the concentration-response curves for S-NO-Cap in NTG-tolerant coronary arteries were not significantly different from those in nontolerant coronary arteries. Captopril (5 x 10(-4) M) did not enhance the vasodilative effect of NTG or reverse NTG tolerance. The NTG-induced increase in cGMP was abolished after NTG tolerance was established. On the other hand, the S-NO-Cap-induced increase in cGMP was unaffected by NTG tolerance. In conclusion, these findings indicate that (1) S-NO-Cap is an NO-like substance, (2) an impaired formation of NO or S-nitrosothiol is responsible for the formation of NTG tolerance and (3) S-NO-Cap, which does not show cross-tolerance with NTG, may serve as a therapeutic alternative to current nitrovasodilators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531088

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Comparison of the vasorelaxant effect of nitroprusside and nitroglycerin in the human radial artery in vitro.

Authors:  G W He; C Q Yang
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

3.  Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.

Authors:  Cynthia Sung; Tom J Parry; Todd A Riccobene; Angela Mahoney; Viktor Roschke; James Murray; Mi Li Gu; Jeffrey K Glenn; Florence Caputo; Cindy Farman; Daniel J Odenheimer
Journal:  AAPS PharmSci       Date:  2002

Review 4.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.